• That the Neglected May Live

Dedicated to saving the life of every rare cancer patient.

WHEN IT COMES TO CANCER, RARE ISN’T RARE.

When taken in aggregate, “rare” cancers are the 3rd leading cause of death in the U.S. and account for 42% of all cancer diagnoses. Defined as affecting fewer than 200,000 persons in the U.S., there are actually more than 250 known types of rare cancer and yet only 38 have approved targeted therapies. SHEPHERD identifies rare cancers without therapies and becomes the development expert for that disease.

icon_list_4th_64x64LEADING CAUSE OF DEATH IN U.S. TAKEN IN AGGREGATE
icon_list_14m_64x64OF ALL CANCER DIAGNOSES ARE CONSIDERED “RARE”
icon_list_250_64x64KNOWN TYPES OF RARE CANCER

FINDING CURES

The time is now, the tools exist, there is no other option – for those diagnosed, or us.

Our goal is to find and guide cures for patients diagnosed with rare cancers. We focus on areas of high, unmet need; rare cancer indications with high mortality rates and few therapeutic options beyond resection and radiation.  We strive to match each biological target with the optimal platform (small molecule, antibody, targeted nanoparticle). All projects in our pipeline are currently in a preclinical phase of development in collaboration with the National Cancer Institute, University College London, and the Massachusetts Institute of Technology.

Our criteria for indication selection:

Availability of therapeutic AGENTS and/or potential PARTNERS.

Clear, targetable BIOLOGY supported by STRONG genetic and experimental EVIDENCE.

RESOURCES from existing research FOUNDATIONS and RESEARCHERS

MEET THE TEAM

Focused on Saving Lives

EUGENE “GENE” WILLIAMS

Co-Founder & Executive Chairman
Gene Williams is the Executive Chairman of ProMIS Neurosciences, a publicly traded biotech focused on therapy development for Alzheimer’s disease. As former Senior Vice President of Program and Portfolio Management at Genzyme, Gene comes to SHEPHERD with expert knowledge on commercialization integration, drug development, and deal making.

Eugene

DAVID HYSONG

Founder, Patient & Chief Executive Officer
David Hysong has had a lifelong desire to risk his own life to save the lives of others. When an early cancer diagnosis blocked his intended path in Special Operations and anti-human trafficking work, he forged another. One that has the potential to save far more lives than he had ever dreamed. At SHEPHERD, we want to be a “million life idea.” And that is the SHEPHERD promise – to never stop fighting until every rare cancer patient lives.

David

DR. JOHANNE KAPLAN

Chief Scientific Officer
Johanne comes to SHEPHERD from Genzyme, where she served as Vice President of Research. Over the course of her 24-year career in biotechnology, Johanne directed pioneering research and partnerships leading to the implementation of multiple clinical trials in the fields of gene therapy, autoimmunity, and oncology. She led the scientific research support of several approved drugs in the oncology space including alemtuzumab, clofarabine, and plerixafor.

Johanne

ELIZABETH HOSTETTER

Chief Operating Officer
Elizabeth joins SHEPHERD having spent most of her career as a consultant at Bain & Company, where she advised companies across sectors to grow profitability, optimize costs and launch commercial products. At Bain, Elizabeth developed a passion for analytical problem solving, processes, team building—and most importantly— a renewed commitment to healthcare.

Elizabeth

DR. JAMIE DEMPSEY BARBER

Chief Research Officer
Jamie is former head teaching fellow for both molecular and cellular biology courses at Harvard University, as well as instructor of “The Biology of Cancer” course at Harvard Extension School. Her expertise covers cancer-related molecular and cellular mechanisms, as well as therapeutic management.

Jamie

LACIE RANDALL

Chief Creative Officer
With an intensive background in Marketing and Communication, Lacie has helped create multiple American Advertising Award-winning campaigns for both nonprofit and for-profit organizations. Her recent work includes such companies as Major League Baseball and the National Football League, Publix, and Hermès.

Lacie

JON GOETZ

Strategic Research Analyst
A passionate reader and writer, Jon has pursued opportunities in education and mentorship both academically and professionally. As an undergraduate, Jon worked with Breakthrough Collaborative, a national nonprofit seeking to increase academic opportunity for highly motivated, underserved students and put them on a college trajectory.

Jon

INTERNS

Chloe Herzog  |  Chris Higginson  |  Emily Zeme

HISTORY

A Rage to Live

David Hysong has had a lifelong desire to risk his own life to save the lives of others. When an early cancer diagnosis blocked his intended path in Special Operations and anti-human trafficking work, he forged another. One that has the potential to save far more lives than he had ever dreamed. At SHEPHERD, we want to be a “million life idea.” And that is the SHEPHERD promise – to never stop fighting until every rare cancer patient lives.

STAY IN TOUCH

We’d love to keep you involved every step of the way. Just complete the form below and you’re in…